LOG IN
SIGN UP
MARKET
SONN
SONN
Sonnet Biotherapeutc Hldng Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.2800
+0.0044
+1.60%
After Hours: 0.2800 0 0.00% 19:54 06/24 EDT
OPEN
0.2712
PREV CLOSE
0.2756
HIGH
0.2950
LOW
0.2700
VOLUME
733.62K
TURNOVER
0
52 WEEK HIGH
2.070
52 WEEK LOW
0.2280
MARKET CAP
16.96M
P/E (TTM)
-0.4083
1D
5D
1M
3M
1Y
5Y
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
44 Stocks Moving In Friday's Mid-Day Session
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Benzinga · 06/10 16:07
Mid-Afternoon Market Update: Skillsoft Falls After Q1 Results; Applied UV Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 1% on Thursday.
Benzinga · 06/09 18:37
Mid-Day Market Update: Dow Drops 150 Points; Bluejay Diagnostics Shares Jump
U.S. stocks traded lower midway through trading, with the Dow Jones dropping 150 points on Thursday.
Benzinga · 06/09 16:20
Sonnet Bio surges 35% on pre-clinical data for lead asset
Clinical-stage biotech Sonnet BioTherapeutics (NASDAQ:SONN) announced on Thursday that its lead candidate in combination with a commercially available anti-PD1 therapy generated compelling data in a preclinical model. After the news,
Seekingalpha · 06/09 12:38
BRIEF-Sonnet Biotherapeutics Announces Results From Preclinical Combination Study Of SON-1010 With Anti-PD1 Checkpoint Inhibition
reuters.com · 06/09 11:35
Sonnet BioTherapeutics Announces Results From A Preclinical Combination Study Of SON-1010 With anti-PD1 Checkpoint Inhibition
Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-FHAB) and a commercially available anti-PD1 antibody Combination of SON-1010 with anti-PD1 increased survival rate These
Benzinga · 06/09 11:03
Sector Update: Health Care
MT Newswires · 06/09 08:56
No Data
Learn about the latest financial forecast of SONN. Analyze the recent business situations of Sonnet Biotherapeutc Hldng Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 2 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SONN stock price target is 2.250 with a high estimate of 2.500 and a low estimate of 2.000.
Current 0.2800
EPS
Actual
Estimate
-0.22-0.16-0.11-0.05
Institutional Holdings
Institutions: 31
Institutional Holdings: 6.18M
% Owned: 10.20%
Shares Outstanding: 60.59M
TypeInstitutionsShares
Increased
6
1.57M
New
7
1.17M
Decreased
3
699.70K
Sold Out
2
62.45K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+2.68%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/President/Chief Executive Officer/Director
Pankaj Mohan
Chief Financial Officer
John Cross
Chief Scientific Officer
John Cini
Other
Susan Dexter
Other
Richard Kenney
Director
Donald Griffith
Independent Director
Nailesh Bhatt
Independent Director
Albert Dyrness
Independent Director
Raghu Rao
No Data
No Data
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company’s technology, namely fully human albumin binding (FHAB) helps to develop biologic medicines. FHAB utilizes a fully human single chain antibody fragment linked to either one or two therapeutic molecules capable of affecting single or bispecific mechanisms of action. The FHAB construct contains a domain, which is designed to bind to and hitch hike on human serum albumin for transport to targets, such as solid tumors or to the lymphatic system. It designed the construct to improve drug accumulation in specific tissues, as well as to extend the duration of activity in the body. FHAB development candidates are produced in a mammalian cell culture, which enables glycosylation, thereby reducing the risk of immunogenicity. FHAB technology can help in drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory and hematological conditions.
Webull offers kinds of Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ:SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.